Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Leukemia, Myeloid, Acute 3Head and Neck Neoplasms 3Lymphoma, T-Cell, Peripheral 2Lymphoma 2Thyroid Neoplasms 1Pancreatic Neoplasms 1NSCLC 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Myelomonocytic, Chronic 1Hereditary Sensory and Autonomic Neuropathies 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Injections 24pembrolizumab 13toripalimab 12tislelizumab 9Gemcitabine 7Cisplatin 7Carboplatin 6atezolizumab 5Nivolumab 5Irinotecan 5Pemetrexed 4Oxaliplatin 4Leucovorin 4Fluorouracil 4Docetaxel 4Cetuximab 4trastuzumab deruxtecan 3spartalizumab 3cediranib 3Paclitaxel 3PM 01183 3Capecitabine 3sintilimab 2olaparib 2lenvatinib 2glumetinib 2camrelizumab 2apatinib 2Therapeutics 2Midazolam 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Tumor × tipifarnib × Clear all
NCT04865159 2023-09-21

Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies

Kura Oncology, Inc.

Phase 1 Terminated
6 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡